In Brief: OraVax/bioMerieux Vitek:
This article was originally published in The Gray Sheet
OraVax/bioMerieux Vitek: Enter licensing agreement under which St. Louis, Missouri-based bioMerieux gains exclusive, worldwide rights to develop diagnostic tests incorporating Cambridge, Massachusetts-based OraVax's proprietary CagA Helicobacter pylori antigen. OraVax is investigating use of the CagA antigen for use in H. pylori vaccines...
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.